Table 1.
Baseline characteristics of study objects.
| Training group (n = 171) | Validation group (n = 91) | P value | |
|---|---|---|---|
| Age | 66.96 ± 12.08 | 65.75 ± 11.28 | .418 |
| Gender | .994 | ||
| Male | 103 (60.2%) | 54 (59.3%) | |
| Female | 68 (39.8%) | 37 (40.7%) | |
| Vertical diameter (mm) | 34.03 ± 12.79 | 35.89 ± 13.06 | .271 |
| Transverse diameter (mm) | 15.68 ± 5.81 | 17.08 ± 8.03 | .241 |
| CEA | .604 | ||
| (−, ≤5 ng/mL) | 83 (48.5%) | 48 (52.7%) | |
| (+, >5 ng/mL) | 88 (51.5%) | 43 (47.3%) | |
| CA19-9 | .771 | ||
| (−, ≤35 U/mL) | 163 (95.3%) | 86 (94.5%) | |
| (+, >35 U/mL) | 8 (4.7%) | 5 (5.5%) | |
| CA125 | 1.000 | ||
| (−, ≤35 U/mL) | 168 (98.2%) | 90 (98.9%) | |
| (+, >35 U/mL) | 3 (1.8%) | 1 (1.1%) | |
| pT_stage | .487 | ||
| T1 | 3 (1.8%) | 3 (3.3%) | |
| T2 | 58 (33.9%) | 36 (39.6%) | |
| T3 | 108 (63.2%) | 50 (54.9%) | |
| T4 | 2 (1.2%) | 2 (2.2%) | |
| pN_stage | .409 | ||
| N0 | 107 (62.6%) | 57 (62.6%) | |
| N1a | 21 (12.3%) | 15 (16.5%) | |
| N1b | 21 (12.3%) | 7 (7.7%) | |
| N1c | 12 (7%) | 6 (6.6%) | |
| N2a | 9 (5.3%) | 3 (3.3%) | |
| N2b | 1 (0.6%) | 3 (3.3%) | |
| Differentiation | .810 | ||
| Lower | 50 (29.2%) | 30 (33%) | |
| Middle | 116 (67.8%) | 59 (64.8%) | |
| Untested | 5 (2.9%) | 2 (2.2%) | |
| Microstate status | .554 | ||
| Unstable | 3 (1.8%) | 0 (0%) | |
| Stable | 168 (98.2%) | 91 (100%) | |
| Ki-67 | 0.52 ± 0.17 | 0.5 ± 0.18 | .868 |
| TDs count {median (Q1–Q3)} | 0 (0–0) | 0 (0–0) | .219 |
| MRF | .422 | ||
| (−) | 157 (91.8%) | 81 (89%) | |
| (+) | 10 (5.8%) | 5 (5.5%) | |
| Untested | 4 (2.3%) | 5 (5.5%) | |
| Location | .353 | ||
| Lower(<5 cm) | 80 (46.8%) | 51 (56%) | |
| Middle(≤5 to ≤ 10 cm) | 76 (44.4%) | 34 (37.4%) | |
| Upper (>10 cm) | 15 (8.8%) | 6 (6.6%) | |
| CT_stage | .433 | ||
| T1~2 | 102 (59.6%) | 54 (59.3%) | |
| T3 | 66 (38.6%) | 33 (36.3%) | |
| T4 | 3 (1.8%) | 4 (4.4%) | |
| Perirectal_nodes (>3 mm) | 1 (0~3) | 1 (0~2) | .344 |
CA125 = carbohydrate antigen125, CA19-9 = carbohydrate antigen19-9, CEA = carcinoembryonic antigen, MRF = mesorectal fascia, TD = tumor deposition.